Loading...
PeptiDream Inc.
4587.T•JPX
HealthcareBiotechnology
$1712.00
$-138.50(-7.48%)
PeptiDream Inc. (4587.T) Stock Overview
Explore PeptiDream Inc.’s financial performance, market position, analyst ratings, and future outlook.
Revenue Growth
62.57%
↑ 62.57%
Profit Growth
$115.85
↑ 394.59%
EPS Growth
$115.85
↑ 394.87%
Operating Margin
45.31%
↑ 211.73%
ROE
28.07%
↑ 394.59%
Dividend Yield
0.00%
Analyst Recommendations data is not available for 4587.TAnalyst Recommendations details for 4587.T are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Company Profile
PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. The company develops its products based on its Peptide Discovery Platform System, a drug finding platform for the development of peptides. It has a collaborative research and exclusive license agreement with Takeda Pharmaceutical Company Limited to develop peptide drug conjugates for neuromuscular diseases. The company was incorporated in 2006 and is headquartered in Kawasaki, Japan.
CEO
Dr. Patrick Crawford Reid Ph.D.
Employees
621
Headquarters
3-25-23 Tonomachi, Kawasaki
Founded
2013